Our Principle

Dr Jo Kilgour BSc, MSc, PhD, ERT

Our Principle is Jo Kilgour, an internationally respected toxicologist, specialising in inhalation toxicology. After leaving AstraZeneca in 2015, Jo founded and is Director of Mereside Toxicology Consulting Ltd, a toxicology consultancy company specialising in inhalation toxicology applied to the development of pharmaceutical and agrochemical/chemical products.

Jo’s experience includes:

  • Project management from early research to full development
  • Non-clinical strategy/program design
  • Initiation, conduct and monitoring of toxicology studies
  • Report compilation and review
  • Regulatory submissions (document preparation, responses and interactions)
  • Impurities/specification issues
  • Life cycle management of established products
  • Toxicology representation on Inter-Industry consortia
  • Design and management of investigative toxicology programmes
  • Due diligence
  • Expert review
  • Training and education

Jo has held a number of key positions as Project Toxicologist in AstraZeneca and Syngenta (Central Toxicology Laboratory). Jo also maintains a high profile externally through leadership of key societies, and by speaking at many courses and conferences. These include an educational workshop on inhalation toxicology run by the FDA for its regulators, British Toxicology Society (BTS) and Association of Inhalation Toxicologists (AIT) annual conferences, and most recently Jo was an invited speaker at the “Inhaled drug development” session of the Drug Delivery Congress Europe in Berlin. Jo is past Chair of the Education Sub-Committee of the BTS and is the current Chair of the AIT.

Jo remains at the forefront of emerging science and regulatory developments through involvement in activities which shape the techno-regulatory landscape. Examples include the ILSI-HESI emerging issues workshop on induced alveolar macrophage (AM) responses, for which Jo was a member of the organising committee and co-author of the published proceedings (Forbes et al, 2014), and the current NC3Rs CRACK-IT inhalation translation challenge, a cross-industry collaboration which aims to develop longitudinal, non-invasive methods for monitoring induced AM responses.